title: Evaluation of factor V Leiden, prothrombin and methylenetetrahydrofolate reductase gene mutations in patients with severe pregnancy complications in northern Finland.
abstract: BACKGROUND
  Thrombosis in placenta may lead to severe pregnancy complications. Most important inherited thrombophilias are factor V Leiden mutation, prothrombin mutation, and methylenetetrahydrofolate reductase mutation. The aim of our research was to evaluate the prevalence of inherited thrombophilias in severe pregnancy complications and in normal pregnancies.
  
  
  METHODS
  The study subjects with severe preeclampsia, intrauterine growth restriction, placental abruption or fetal death were collected during the period 1999-2004 from Oulu University Hospital. We also collected during the same period voluntary parturients with normal pregnancy outcome as the control group. FVL, FII, and MTHFR gene mutations of the patients and controls were analyzed.
  
  
  RESULTS
  We found a significant difference in the prevalence of FVL mutation between the groups. There were 9.5% FVL mutations in the study group compared to 1.8% in the control group; the observed difference between prevalences was 7.7% (95% CI 2.0-13.4). No statistical difference was found in the FII or MTHFR mutations between the groups. All FV and FII mutations were heterozygous and all the MTHFR mutations homozygous.
  
  
  CONCLUSIONS
  Women with thrombophilia have a risk for severe pregnancy complications. Randomized controlled trials are needed to assess the influence of low-molecular-weight heparin in pregnant women with thrombophilia.
authors.affiliation: Department of Obstetrics and Gynecology, Oulu University Hospital, Oulu, Finland.
authors.forename: J
authors.initials: J
authors.lastname: Jarvenpaa
authors.forename: M
authors.initials: M
authors.lastname: Pakkila
authors.forename: E-R
authors.initials: ER
authors.lastname: Savolainen
authors.forename: A
authors.initials: A
authors.lastname: Perheentupa
authors.forename: I
authors.initials: I
authors.lastname: Jarvela
authors.forename: M
authors.initials: M
authors.lastname: Ryynanen
mesh_terms: D016022:Case-Control Studies; D005165:Factor V / Q000032:analysis / Q000235:genetics*; D005260:Female; D005387:Finland / Q000453:epidemiology; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000032:analysis / Q000235:genetics*; D009154:Mutation; D011225:Pre-Eclampsia; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000209:etiology* / Q000235:genetics / Q000473:pathology / Q000503:physiopathology; D015995:Prevalence; D011516:Prothrombin / Q000032:analysis / Q000235:genetics*; D012189:Retrospective Studies; D012720:Severity of Illness Index
chemical_list: C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin; D042965:Methylenetetrahydrofolate Reductase (NADPH2)